NasdaqGS:IBRXBiotechs
A Look At ImmunityBio (IBRX) Valuation As ResQ215B Phase 2 Trial Progresses
Why the ResQ215B trial matters for ImmunityBio (IBRX)
ImmunityBio (IBRX) has kicked off the ResQ215B Phase 2 trial, testing a chemotherapy free, lymphodepletion free outpatient immunotherapy regimen for patients with indolent B cell non Hodgkin lymphoma, including Waldenström’s Macroglobulinemia.
The study combines CD19 targeted high affinity NK cell therapy, ANKTIVA, and rituximab, building on earlier Phase 1 data in which a small Waldenström’s cohort achieved 100% disease control without...